Literature DB >> 8363388

Suramin prevents duck hepatitis B virus infection in vivo.

W B Offensperger1, S Offensperger, E Walter, H E Blum, W Gerok.   

Abstract

The effect of suramin on duck hepatitis B virus (DHBV) infection was investigated in vivo. Suramin pretreatment of Pekin ducklings completely prevented DHBV infection. In contrast, suramin given at the time of or after inoculation with DHBV did not inhibit viral infection, replication, or gene expression. These data indicate that suramin effectively blocks the early stages of DHBV infection in vivo.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8363388      PMCID： PMC188009          DOI： 10.1128/AAC.37.7.1539

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Inhibition of lysozyme by 'Suramin'.

Authors:  I LOMINSKI; S GRAY
Journal:  Nature       Date:  1961-11-18       Impact factor: 49.962

2.  Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus.

Authors:  W S Mason; G Seal; J Summers
Journal:  J Virol       Date:  1980-12       Impact factor: 5.103

3.  Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

Authors:  H Mitsuya; M Popovic; R Yarchoan; S Matsushita; R C Gallo; S Broder
Journal:  Science       Date:  1984-10-12       Impact factor: 47.728

4.  Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses.

Authors:  E De Clercq
Journal:  Cancer Lett       Date:  1979-11       Impact factor: 8.679

5.  Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection.

Authors:  J M Collins; R W Klecker; R Yarchoan; H C Lane; A S Fauci; R R Redfield; S Broder; C E Myers
Journal:  J Clin Pharmacol       Date:  1986-01       Impact factor: 3.126

6.  Suramin inhibits duck hepatitis B virus DNA polymerase activity.

Authors:  K Tsiquaye; A Zuckerman
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

7.  Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo.

Authors:  S Broder; R Yarchoan; J M Collins; H C Lane; P D Markham; R W Klecker; R R Redfield; H Mitsuya; D F Hoth; E Gelmann
Journal:  Lancet       Date:  1985-09-21       Impact factor: 79.321

8.  Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation.

Authors:  V Eisen; C Loveday
Journal:  Br J Pharmacol       Date:  1973-12       Impact factor: 8.739

9.  In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus.

Authors:  J S Tuttleman; J C Pugh; J W Summers
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

10.  Suramin binds to platelet-derived growth factor and inhibits its biological activity.

Authors:  M Hosang
Journal:  J Cell Biochem       Date:  1985       Impact factor: 4.429
View more
  9 in total

1.  Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles.

Authors:  O Hantz; C Borel; C Trabaud; F Zoulim; J Dessolin; M Camplo; P Vlieghe; M Bouygues; C Trepo; J L Kraus
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 2.  100 Years of Suramin.

Authors:  Natalie Wiedemar; Dennis A Hauser; Pascal Mäser
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 3.  Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.

Authors:  Florian A Lempp; Yi Ni; Stephan Urban
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-08-18       Impact factor: 46.802

4.  Itinerary of hepatitis B viruses: delineation of restriction points critical for infectious entry.

Authors:  Anneke Funk; Mouna Mhamdi; Li Lin; Hans Will; Hüseyin Sirma
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

5.  Spread of hepatitis B viruses in vitro requires extracellular progeny and may be codetermined by polarized egress.

Authors:  A Funk; H Hohenberg; M Mhamdi; H Will; H Sirma
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

6.  HBV life cycle: entry and morphogenesis.

Authors:  Stephanie Schädler; Eberhard Hildt
Journal:  Viruses       Date:  2009-09-01       Impact factor: 5.048

7.  The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo.

Authors:  Peijun Ren; Gang Zou; Benjamin Bailly; Shanshan Xu; Mei Zeng; Xinsheng Chen; Liang Shen; Ying Zhang; Patrice Guillon; Fernando Arenzana-Seisdedos; Philippe Buchy; Jian Li; Mark von Itzstein; Qihan Li; Ralf Altmeyer
Journal:  Emerg Microbes Infect       Date:  2014-09-03       Impact factor: 7.163

Review 8.  Structure(s), function(s), and inhibition of the RNA-dependent RNA polymerase of noroviruses.

Authors:  Jerome Deval; Zhinan Jin; Ying-Chih Chuang; C Cheng Kao
Journal:  Virus Res       Date:  2016-12-29       Impact factor: 3.303

9.  Proteoglycans act as cellular hepatitis delta virus attachment receptors.

Authors:  Oscar Lamas Longarela; Tobias T Schmidt; Katrin Schöneweis; Raffaella Romeo; Heiner Wedemeyer; Stephan Urban; Andreas Schulze
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.